<DOC>
	<DOCNO>NCT02671955</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability JNJ-61610588 participant advance cancer order determine recommend Phase 2 dose ( RP2D ) evaluation specific tumor type .</brief_summary>
	<brief_title>A Study Safety , Pharmacokinetics , Pharmacodynamics JNJ-61610588 Participants With Advanced Cancer</brief_title>
	<detailed_description>The purpose study see JNJ-61610588 safe useful treat participant advanced cancer . This study consist 4 part . Part 1 determine dose JNJ-61610588 give safely advanced cancer participant . Part 2 look participant metastatic non-small cell lung cancer respond safe dose JNJ-61610588 . Parts 3 4 test whether dose JNJ-61610588 identify Part 1 safe effective therapy participant specific type advance cancer ( lung , pancreas , cervical , colorectal , head neck ) . Participants receive study drug outpatient set . Participants safety monitor throughout study .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>The participant solid tumor . Parts 2 3 limited participant nonsmall cell lung cancer . Part 4 limited participant small cell lung , head neck , pancreatic , colorectal , cervical cancer Tumor progression follow least one prior standard therapy The participant radiographically measurable tumor . Evaluable disease acceptable Part 1 The participant willing consent provide tumor tissue sample ( fresh biopsy ) ( Parts 2 3 ) ( Part 2 ) receiving study drug The participant able carry daily life activity without difficulty The participant significant side effect previous anticancer treatment The participant adequate organ blood cell count Sexually active participant must use medically acceptable method contraception course study The participant history major surgery treatment cancer therapy within 26 week start study The participant untreated brain tumor Current severe , uncontrolled systemic disease include ongoing , active infection require treatment antibiotic The participant high blood pressure diabetes wellcontrolled medication History clinically significant heart problem History severe side effect toimmunotherapy The participant pregnant , breastfeeding , plan become pregnant father child Positive Hepatitis B , Hepatitis C , HIV The participant receive anticoagulant therapy exception aspirin within 1 week start study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Advanced Cancer</keyword>
	<keyword>JNJ-61610588</keyword>
</DOC>